Dylan Bram Crotty Sells 441 Shares of Stryker (NYSE:SYK) Stock

Stryker Corporation (NYSE:SYK) insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Stryker Stock Down 2.3%

Shares of SYK opened at $322.20 on Friday. The firm has a fifty day moving average price of $328.64 and a 200-day moving average price of $331.47. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $123.58 billion, a P/E ratio of 33.39, a P/E/G ratio of 2.10 and a beta of 0.76. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter last year, the firm posted $3.13 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Analysts Set New Price Targets

Several brokerages recently issued reports on SYK. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Robert W. Baird set a $385.00 target price on Stryker in a research report on Friday, May 1st. Piper Sandler lowered their target price on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Truist Financial increased their price target on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Finally, Citigroup restated a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Institutional Trading of Stryker

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Gables Capital Management Inc. purchased a new stake in shares of Stryker during the 2nd quarter worth $25,000. Kilter Group LLC purchased a new position in Stryker in the second quarter valued at about $25,000. Highland Investment Advisors LLC purchased a new position in Stryker in the second quarter valued at about $25,000. Godfrey Financial Associates Inc. bought a new position in Stryker in the fourth quarter worth about $26,000. Finally, Sankala Group LLC purchased a new stake in shares of Stryker during the fourth quarter valued at about $26,000. Institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.